Analysis of the association between diabetic nephropathy and polymorphismsin the aldose reductase gene in Type 1 and Type 2 diabetes mellitus

Citation
M. Neamat-allah et al., Analysis of the association between diabetic nephropathy and polymorphismsin the aldose reductase gene in Type 1 and Type 2 diabetes mellitus, DIABET MED, 18(11), 2001, pp. 906-914
Citations number
36
Categorie Soggetti
Endocrynology, Metabolism & Nutrition
Journal title
DIABETIC MEDICINE
ISSN journal
07423071 → ACNP
Volume
18
Issue
11
Year of publication
2001
Pages
906 - 914
Database
ISI
SICI code
0742-3071(200111)18:11<906:AOTABD>2.0.ZU;2-7
Abstract
Aims To investigate the association between polymorphisms of the aldose red uctase gene and diabetic nephropathy in both Type 1 and Type 2 diabetes mel litus, and to carry out a meta-analysis of published results. Methods We have investigated the role of two aldose reductase polymorphisms in four independent cohorts of cases and controls (two each with Type 1 an d Type 2 diabetes) drawn from two ethnic populations, including 471 patient s with nephropathy and 494 control diabetic patients without nephropathy. A C/T transition at position -106, and a (CA)(n) microsatellite marker 2.1 k b from the start site of the aldose reductase gene were genotyped in nephro pathic patients and non-nephropathic controls from each cohort. Results Carriage of the -106 T allele was significantly associated with dia betic nephropathy in three of the four study groups. The Mantel-Haenszel co mbined odds ratio was 2.22 (95% Cl 1.69, 2.94), P = 1.05 x 10(-8). We found no evidence for association of the microsatellite marker with nephropathy, despite moderate levels of disequilibrium between the two markers. Meta-an alysis of published data yielded no evidence for association of the microsa tellite marker with diabetic nephropathy in Type 2 diabetes, but varying de grees of association with diabetic nephropathy in Type 1 diabetes. Conclusions Meta-analyses provide more convincing evidence of a role for th e ALR2-106 marker than for the microsatellite marker in diabetic nephropath y (DN). More studies are now required to confirm these results and to estab lish whether the ALR2-106 polymorphism has a functional role in DN.